High cancer drug prices significantly contribute to health care costs in the United States, with the average annual price of new cancer drugs increasing from less than $10,000 before 2000 to $145,000 in 2015. Baker Institute fellows Hagop M. Kantarjian and Vivian Ho highlight this issue and propose possible solutions.
This policy brief is part of a series of recommendations from the Baker Institute for the incoming president’s administration.
Jan. 20, 2017, 5:55 p.m.
Rachel Tolbert Kimbro, Ph.D., is an associate professor of sociology at Rice University, where she is also the ...
Kirstin R.W. Matthews, Ph.D., is a fellow in science and technology policy at the Baker Institute. She is ...
June 08, 2018
Prescription drug expenditures are projected to reach $360.2 billion in 2018. Per capita spending on ...
December 12, 2018
Human embryo research is restricted in many countries to the first 14 days of development, ...
